TrialCompass TCL
Back to results
Phase 1, Phase 2RecruitingPriority 2 · High priorityNCT04068597

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

ClinicalTrials.gov

Plain-language summary

This Phase 1, Phase 2 trial is comparing CCS1477, Pomalidomide, and other medications against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 6 US locations across multiple states.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

CCS1477 (DRUG): Oral capsule | Pomalidomide (DRUG): oral capsule | Dexamethasone (DRUG): oral tablet | Azacitidine (DRUG): Powder suspension for Injection | Venetoclax (DRUG): Oral tablet | Bortezomib (DRUG): Powder for solution for injection | Ixazomib (DRUG): Oral capsule | Elranatamab (DRUG): Solution for injection | Teclistamab (DRUG): Solution for injection | Lenalidomide (DRUG): Oral capsule | Daratumumab (DRUG): Solution for injection, concentrate for solution for infusion

Drugs / treatments
CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax, Bortezomib, Ixazomib, Elranatamab, Teclistamab, Lenalidomide, Daratumumab
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT04068597

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 1, Phase 2 trial is comparing CCS1477, Pomalidomide, and other medications against other options for people whose T-cell lymphoma has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 6 US locations across multiple states.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

CCS1477 (DRUG): Oral capsule | Pomalidomide (DRUG): oral capsule | Dexamethasone (DRUG): oral tablet | Azacitidine (DRUG): Powder suspension for Injection | Venetoclax (DRUG): Oral tablet | Bortezomib (DRUG): Powder for solution for injection | Ixazomib (DRUG): Oral capsule | Elranatamab (DRUG): Solution for injection | Teclistamab (DRUG): Solution for injection | Lenalidomide (DRUG): Oral capsule | Daratumumab (DRUG): Solution for injection, concentrate for solution for infusion

Drugs / treatments: CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax, Bortezomib, Ixazomib, Elranatamab, Teclistamab, Lenalidomide, Daratumumab

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 250 patients

Primary endpoint: Incidence of treatment-related adverse events; Incidence of laboratory abnormalities

Ages: 18 Years to —

Start date: 2019-08-09 | Est. completion: 2027-03-31

Locations

6 US sites · 39 total

Georgia, Indiana, Maryland, Nebraska, Pennsylvania

Contact

Tomasz Knurowski, PhD | Tomasz.Knurowski@cellcentric.com | 07882871299

Sponsor: CellCentric Ltd. (INDUSTRY)

Tags

All T-cell lymphomas · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT04068597

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.